MX345540B - Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos. - Google Patents
Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos.Info
- Publication number
- MX345540B MX345540B MX2014013271A MX2014013271A MX345540B MX 345540 B MX345540 B MX 345540B MX 2014013271 A MX2014013271 A MX 2014013271A MX 2014013271 A MX2014013271 A MX 2014013271A MX 345540 B MX345540 B MX 345540B
- Authority
- MX
- Mexico
- Prior art keywords
- optical density
- cancer cells
- drug
- well plate
- relative effectiveness
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
- G01N21/17—Systems in which incident light is modified in accordance with the properties of the material investigated
- G01N21/59—Transmissivity
- G01N21/5907—Densitometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/30—Prediction of properties of chemical compounds, compositions or mixtures
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16C—COMPUTATIONAL CHEMISTRY; CHEMOINFORMATICS; COMPUTATIONAL MATERIALS SCIENCE
- G16C20/00—Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
- G16C20/90—Programming languages; Computing architectures; Database systems; Data warehousing
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Computing Systems (AREA)
- Theoretical Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Bioinformatics & Computational Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Software Systems (AREA)
- Databases & Information Systems (AREA)
- Investigating Or Analysing Materials By Optical Means (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medical Treatment And Welfare Office Work (AREA)
Abstract
Se provee un sistema de computadora para determinar la efectividad relativa de fármacos anti-cancerígenos. La interfase tiene opciones seleccionables, incluyendo una opción para manejar los parámetros de prueba del fármaco, y permite al usuario la selección de parámetros de prueba de fármaco deseados con relación a una placa con pocillos virtual asociada con una placa de pocillos física de un espectrofotómetro. El sistema de computadora causa que el espectrofotómetro inicie una prueba de fármaco, en donde la placa de pocillos física incluye al menos un pocillo de prueba que contiene células cancerígenas viables; y al menos un fármaco candidato en una concentración predeterminada; y al menos un pocillo de control con las células cancerígenas viables sola. El sistema registra la densidad óptica del pocillo a una longitud de onda predeterminada a intervalos de tiempo seleccionados por una duración de tiempo seleccionada, y almacena las mediciones de la densidad óptica y tiempo en la base de datos. Se calcula un valor de actividad de las mediciones de la densidad óptica y tiempo, y se despliega una correlación entre el valor de la actividad y la habilidad del fármaco candidato para inducir apoptosis en las células cancerígenas.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261641610P | 2012-05-02 | 2012-05-02 | |
| US13/803,623 US9476871B2 (en) | 2012-05-02 | 2013-03-14 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| PCT/US2013/039189 WO2013166233A1 (en) | 2012-05-02 | 2013-05-02 | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014013271A MX2014013271A (es) | 2015-04-08 |
| MX345540B true MX345540B (es) | 2017-02-03 |
Family
ID=49514877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014013271A MX345540B (es) | 2012-05-02 | 2013-05-02 | Sistema y metodo para la determinacion automatizada de la efectividad relativa de candidatos de farmaco anti-cancerigenos. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US9476871B2 (es) |
| EP (2) | EP4134962A1 (es) |
| JP (1) | JP6365988B2 (es) |
| KR (1) | KR102028711B1 (es) |
| CN (1) | CN104412270B (es) |
| AU (2) | AU2013256248B2 (es) |
| BR (1) | BR112014027287A2 (es) |
| CA (1) | CA2872109C (es) |
| CL (1) | CL2014002981A1 (es) |
| CO (1) | CO7190233A2 (es) |
| CR (1) | CR20140551A (es) |
| CU (1) | CU20140125A7 (es) |
| HK (1) | HK1203670A1 (es) |
| IL (1) | IL235455B (es) |
| MX (1) | MX345540B (es) |
| NI (1) | NI201400128A (es) |
| NZ (1) | NZ702526A (es) |
| PE (1) | PE20150299A1 (es) |
| PH (1) | PH12014502687A1 (es) |
| RU (1) | RU2014148543A (es) |
| SG (1) | SG11201407141VA (es) |
| TW (1) | TWI605413B (es) |
| WO (1) | WO2013166233A1 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9476871B2 (en) | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| AU2013263337A1 (en) * | 2012-05-15 | 2014-12-04 | Diatech Oncology | Tumor cell isolation/purification process and methods for use thereof |
| US9460407B2 (en) * | 2013-05-03 | 2016-10-04 | Sap Se | Generating graphical representations of data |
| WO2015171848A2 (en) * | 2014-05-08 | 2015-11-12 | Diatech Oncology, Llc | Synergism and antagonism between multiple anti-cancer agents determined by mick assay |
| JP6521528B2 (ja) * | 2016-04-18 | 2019-05-29 | 富士フイルム株式会社 | 代替医薬品検索装置及び代替医薬品検索方法 |
| US11151604B2 (en) * | 2016-06-10 | 2021-10-19 | International Business Machines Corporation | Revenue management using dynamic customer selection |
| CN110047562B (zh) * | 2019-05-14 | 2021-04-27 | 上海上药第一生化药业有限公司 | 一种基于酶活力测定法的效价检测的信息化结构和方法 |
| US20200388355A1 (en) * | 2019-06-07 | 2020-12-10 | Cary A. Presant | Method and devices for direct apoptosis assay of purified cells |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5068181A (en) * | 1989-12-01 | 1991-11-26 | Akzo N.V. | Method of monitoring reagent delivery in a scanning spectrophotometer |
| US5356793A (en) | 1990-03-15 | 1994-10-18 | Nitta Gelatin Inc. | Method for testing the sensitivity of anticancer drug |
| US6077684A (en) | 1996-11-14 | 2000-06-20 | Vanderbilt University | Automated assay for measuring apoptosis in cell culture |
| CN1220395A (zh) * | 1997-12-15 | 1999-06-23 | 中国科学院生物物理研究所 | 一种基于微量元素分布特征的抗癌药物筛选方法 |
| US6448030B1 (en) | 2000-02-18 | 2002-09-10 | University Of Nevada-Las Vegas | Method for predicting the efficacy of anti-cancer drugs |
| WO2002040702A2 (en) * | 2000-11-09 | 2002-05-23 | Vanderbilt University | Methods for the treatment of cancer and other diseases and methods of developing the same |
| WO2002046750A2 (en) | 2000-11-13 | 2002-06-13 | Vanderbilt University | Methods of predicting chemotherapy response |
| WO2002058533A2 (en) | 2000-11-17 | 2002-08-01 | Slanetz Alfred E | Process for determining target function and identifying drug leads |
| JP2005519610A (ja) * | 2002-03-13 | 2005-07-07 | エフ．ホフマン−ラ ロシュ アーゲー | 薬剤感受性規定因子の選択方法および選択された因子を用いた薬剤感受性の予測方法 |
| US6900058B2 (en) * | 2003-03-11 | 2005-05-31 | Bionostics, Inc. | Control solution for photometric analysis |
| JP2008536128A (ja) * | 2005-04-09 | 2008-09-04 | セル バイオサイエンシズ，インコーポレイテッド | 自動化微小体積アッセイシステム |
| CN1954887A (zh) * | 2005-10-28 | 2007-05-02 | 中国科学院大连化学物理研究所 | 一种体外抗癌药物筛选模型的制备方法 |
| US7736905B2 (en) | 2006-03-31 | 2010-06-15 | Biodesix, Inc. | Method and system for determining whether a drug will be effective on a patient with a disease |
| KR100721927B1 (ko) | 2006-10-31 | 2007-05-28 | 이수앱지스 주식회사 | 암조직에서 암세포를 분리하는 방법 |
| GB2474613A (en) | 2008-07-10 | 2011-04-20 | Nodality Inc | Methods and apparatus related to management of experiments |
| WO2010148252A1 (en) * | 2009-06-17 | 2010-12-23 | Jody Vykoukal | Method and apparatus for quantitative microimaging |
| KR101533469B1 (ko) | 2010-02-03 | 2015-07-02 | 연세대학교 산학협력단 | Ｒａｓ의 Ｔｈｒ-144번과 Ｔｈｒ-148번의 인산화의 감지를 통한 암 진단 방법, 항암제 스크리닝 및 약효테스트 방법 |
| US20110244503A1 (en) * | 2010-03-31 | 2011-10-06 | Perree Mathieu | System and Method for Anti-Cancer Drug Candidate Evaluation |
| US8475739B2 (en) * | 2011-09-25 | 2013-07-02 | Theranos, Inc. | Systems and methods for fluid handling |
| US9476871B2 (en) | 2012-05-02 | 2016-10-25 | Diatech Oncology Llc | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates |
| AU2013263337A1 (en) | 2012-05-15 | 2014-12-04 | Diatech Oncology | Tumor cell isolation/purification process and methods for use thereof |
-
2013
- 2013-03-14 US US13/803,623 patent/US9476871B2/en active Active
- 2013-04-30 TW TW102115445A patent/TWI605413B/zh active
- 2013-05-02 WO PCT/US2013/039189 patent/WO2013166233A1/en active Application Filing
- 2013-05-02 CA CA2872109A patent/CA2872109C/en active Active
- 2013-05-02 EP EP22180904.9A patent/EP4134962A1/en not_active Withdrawn
- 2013-05-02 CN CN201380035279.0A patent/CN104412270B/zh not_active Expired - Fee Related
- 2013-05-02 NZ NZ702526A patent/NZ702526A/en not_active IP Right Cessation
- 2013-05-02 PE PE2014001938A patent/PE20150299A1/es not_active Application Discontinuation
- 2013-05-02 SG SG11201407141VA patent/SG11201407141VA/en unknown
- 2013-05-02 JP JP2015510444A patent/JP6365988B2/ja active Active
- 2013-05-02 MX MX2014013271A patent/MX345540B/es active IP Right Grant
- 2013-05-02 EP EP13784507.9A patent/EP2847701A4/en not_active Ceased
- 2013-05-02 AU AU2013256248A patent/AU2013256248B2/en not_active Ceased
- 2013-05-02 BR BR112014027287A patent/BR112014027287A2/pt not_active Application Discontinuation
- 2013-05-02 KR KR1020147033937A patent/KR102028711B1/ko active IP Right Grant
- 2013-05-02 RU RU2014148543A patent/RU2014148543A/ru not_active Application Discontinuation
-
2014
- 2014-10-31 NI NI201400128A patent/NI201400128A/es unknown
- 2014-11-02 IL IL235455A patent/IL235455B/en not_active IP Right Cessation
- 2014-11-03 CU CU2014000125A patent/CU20140125A7/es unknown
- 2014-11-03 CL CL2014002981A patent/CL2014002981A1/es unknown
- 2014-12-02 CO CO14265404A patent/CO7190233A2/es unknown
- 2014-12-02 PH PH12014502687A patent/PH12014502687A1/en unknown
- 2014-12-02 CR CR20140551A patent/CR20140551A/es unknown
-
2015
- 2015-05-04 HK HK15104231.4A patent/HK1203670A1/xx unknown
-
2016
- 2016-10-04 US US15/285,292 patent/US10488402B2/en active Active
-
2018
- 2018-12-21 AU AU2018282460A patent/AU2018282460B2/en active Active
-
2019
- 2019-10-02 US US16/591,389 patent/US12066427B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12014502687A1 (en) | System and method for automated determination of the relative effectiveness of anti-cancer drug candidates | |
| Derynck et al. | EMT and cancer: more than meets the eye | |
| Quirk et al. | Sustained clearance of superficial basal cell carcinomas treated with imiquimod cream 5%: results of a prospective 5-year study. | |
| SG10201907682RA (en) | System and method for providing patient-specific dosing as a function of mathematical models | |
| AU2019268205A1 (en) | Analysis of glucose median, variability, and hypoglycemia risk for therapy guidance | |
| GB2547355A (en) | System and method for collection, storage and management of medical data | |
| MX2015006757A (es) | Método para la evaluación de la presencia de o riesgo de tumores de colon. | |
| IN2014DN01817A (es) | ||
| Kvachadze et al. | An overview of ethnic and gender differences in pain sensation. | |
| Sehgal et al. | Basal cell carcinoma: pathophysiology. | |
| Yang et al. | Repopulation of tumor cells during fractionated radiotherapy and detection methods | |
| Liu et al. | PD-1 related transcriptome profile and clinical outcome in diffuse gliomas | |
| IN2015DN02508A (es) | ||
| van der Veen et al. | Anchoring molecular mechanisms to the adverse outcome pathway for skin sensitization: Analysis of existing data | |
| MX2014004471A (es) | Fenotipificacion de precision utilizando analisis de proximidad de espacio de puntuacion. | |
| WO2014052685A3 (en) | Devices and methods for single cell analysis | |
| Norfolk et al. | Developing therapeutic rapport: a training validation study. | |
| Ma et al. | Single cell functional proteomics for assessing immune response in cancer therapy: technology, methods, and applications | |
| WO2014040090A3 (en) | System of assessing physiologic status from sweat analysis and determining an appropriate response | |
| WO2013188437A3 (en) | Ex vivo methods to identify circulating drug metabolites with drug interaction potential | |
| TH152624A (th) | ระบบ และวิธีการสำหรับการกำหนดหาแบบอัตโนมัติของประสิทธิผลสัมพัทธ์ ของสารที่มีศักยภาพในการเป็นยาต้านมะเร็ง | |
| MX2017015031A (es) | Metodo para indice de biocomparabilidad. | |
| Liu et al. | Aggressive behavior and elevated lactate dehydrogenase at baseline confer inferior prognosis in patients with primary cutaneous lymphoma | |
| Kettenhofen et al. | Human iPSC-derived Cardiomyocytes: a Predictive, HTS-Scalable Tool for Comprehensive Cardiac Safety | |
| WO2012123947A3 (en) | Method and apparatus for morphological analysis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |